SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines
- 23 Downloads
Cisplatin (DDP)-based chemotherapy is a standard strategy for cervical cancer, while chemoresistance remains a huge challenge. In the present study, we aimed to explore the effects of SPP1 on the proliferation and apoptosis rate of the HeLa cervical cancer cell line with cisplatin (DDP) resistance.
Microarray analysis was employed to select differentially expressed genes in cervical cancer tissues and adjacent tissues. Then, we established a DDP-resistant HeLa cell line (res-HeLa). Western blotting was used to detect SPP1 expression in both tissue and cells. After the transfection with si-SPP1 and pcDNA3.1-SPP1, colony formation and MTT assays were applied to detect cell proliferation changes. Flow cytometry was employed to detect the cell apoptosis rate. Western blotting was performed to verify the activation of PI3K/Akt signal pathway proteins related to DDP resistance.
SPP1 was overexpressed in cervical cancer tissues and cell lines. Compared to normal HeLa cells, expression of SPP1 was significantly enhanced in res-HeLa cells. SPP1 knockdown resulted in repressed proliferation and enhanced apoptosis of res-HeLa cells, which could be reversed by SPP1 overexpression in HeLa cells. Additionally, downregulation of SPP1 improved the DDP sensitivity of HeLa by inhibiting the PI3K/Akt signaling pathway.
SPP1 inhibition could suppress proliferation, induce apoptosis and increase the DDP chemo-sensitivity of HeLa cells.
KeywordsSPP1 Cervical cancer HeLa DDP PI3K/Akt Resistance
Compliance with ethical standards
Conflict of interest
The authors declare that there are no competing interests associated with the manuscript.
All procedures performed in studies involving human participants were in accordance with the ethical standards of General Hospital of Tianjin Medical University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 2.Sun XL, Wang HB, Wang ZQ, Cao TT, Yang X, Han JS, Wu YF, Reilly KH, Wang JL (2017) Effect of transcutaneous electrical stimulation treatment on lower urinary tract symptoms after class III radical hysterectomy in cervical cancer patients: study protocol for a multicentre, randomized controlled trial. BMC Cancer 17(1):416. https://doi.org/10.1186/s12885-017-3387-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Marchetti C, De Felice F, Di Pinto A, Romito A, Musella A, Palaia I, Monti M, Tombolin V, Muzii L, Benedetti Panici P (2018) Survival nomograms after curative neoadjuvant chemotherapy and radical surgery for stage IB2-IIIB cervical cancer. Cancer Res Treat 50(3):768–776. https://doi.org/10.4143/crt.2017.141 CrossRefPubMedGoogle Scholar
- 4.Filippova M, Filippov V, Williams VM, Zhang K, Kokoza A, Bashkirova S, Duerksen-Hughes P (2014) Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents. Biomed Res Int 2014:574659. https://doi.org/10.1155/2014/574659 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627. https://doi.org/10.1146/annurev.med.53.082901.103929 CrossRefPubMedGoogle Scholar
- 7.Agoni L, Basu I, Gupta S, Alfieri A, Gambino A, Goldberg GL, Reddy EP, Guha C (2014) Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. Int J Radiat Oncol Biol Phys 88(5):1180–1187. https://doi.org/10.1016/j.ijrobp.2013.12.051 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Wang B, Huang Z, Gao R, Zeng Z, Yang W, Sun Y, Wei W, Wu Z, Yu L, Li Q, Zhang S, Li F, Liu G, Liu B, Leng L, Zhan W, Yu Y, Yang G, Zhou S (2017) Expression of long noncoding RNA urothelial cancer associated 1 promotes cisplatin resistance in cervical cancer. Cancer Biother Radiopharm 32(3):101–110. https://doi.org/10.1089/cbr.2016.2156 CrossRefPubMedGoogle Scholar
- 9.Casagrande N, De Paoli M, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D (2013) Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. Gynecol Oncol 131(3):744–752. https://doi.org/10.1016/j.ygyno.2013.08.041 CrossRefPubMedGoogle Scholar
- 10.Liu G, Fan X, Tang M, Chen R, Wang H, Jia R, Zhou X, Jing W, Wang H, Yang Y, Yin F, Wei H, Li B, Zhao J (2016) Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells. Cancer Lett 383(2):171–182. https://doi.org/10.1016/j.canlet.2016.09.033 CrossRefPubMedGoogle Scholar
- 11.Qin H, Wang R, Wei G, Wang H, Pan G, Hu R, Wei Y, Tang R, Wang J (2018) Overexpression of osteopontin promotes cell proliferation and migration in human nasopharyngeal carcinoma and is associated with poor prognosis. Eur Arch Otorhinolaryngol 275(2):525–534. https://doi.org/10.1007/s00405-017-4827-x CrossRefPubMedGoogle Scholar
- 13.Ruberti S, Bianchi E, Guglielmelli P, Rontauroli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, Manfredini R (2018) Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Leukemia 32(2):438–449. https://doi.org/10.1038/leu.2017.220 CrossRefPubMedGoogle Scholar
- 14.Hao C, Cui Y, Hu MU, Zhi X, Zhang L, Li W, Wu W, Cheng S, Jiang WG (2017) OPN-a splicing variant expression in non-small cell lung cancer and its effects on the bone metastatic abilities of lung cancer cells in vitro. Anticancer Res 37(5):2245–2254. https://doi.org/10.21873/anticanres.11561 CrossRefPubMedGoogle Scholar
- 15.Kijewska M, Kocyk M, Kloss M, Stepniak K, Korwek Z, Polakowska R, Dabrowski M, Gieryng A, Wojtas B, Ciechomska IA, Kaminska B (2017) The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma. Oncotarget 8(10):16340–16355. https://doi.org/10.18632/oncotarget.14092 CrossRefPubMedGoogle Scholar
- 20.Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, Ravazzolo R (2004) Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genom 20(1):87–96. https://doi.org/10.1152/physiolgenomics.00138.2004 CrossRefGoogle Scholar
- 23.Song JY, Lee JK, Lee NW, Jung HH, Kim SH, Lee KW (2008) Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer. Int J Gynecol Cancer 18(5):1051–1059. https://doi.org/10.1111/j.1525-1438.2007.01164.x CrossRefPubMedGoogle Scholar
- 24.Li F, Guo Y, Han L, Duan Y, Fang F, Niu S, Ba Q, Zhu H, Kong F, Lin C, Wen X (2012) In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus. Oncol Lett 4(6):1254–1258. https://doi.org/10.3892/ol.2012.926 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Qian C, Li P, Yan W, Shi L, Zhang J, Wang Y, Liu H, You Y (2015) Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-kappaB/Bcl2 pathway. Mol Med Rep 11(3):1951–1955. https://doi.org/10.3892/mmr.2014.2951 CrossRefPubMedGoogle Scholar
- 27.Gu T, Ohashi R, Cui R, Tajima K, Yoshioka M, Iwakami S, Sasaki S, Shinohara A, Matsukawa T, Kobayashi J, Inaba Y, Takahashi K (2009) Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer 66(2):176–183. https://doi.org/10.1016/j.lungcan.2009.02.004 CrossRefPubMedGoogle Scholar